NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Williams JW Jr, Slubicki MN, Tweedy DS, et al. Evidence Synthesis for Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications [Internet]. Washington (DC): Department of Veterans Affairs (US); 2009 Oct.

Cover of Evidence Synthesis for Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications

Evidence Synthesis for Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications [Internet].

Show details

REFERENCES

(TEXT AND APPENDICES)

1.
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498–504. [PubMed: 9167458]
2.
Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry. 1992;14(4):237–47. [PubMed: 1505745]
3.
Ormel J, et al. Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry. 1991;48(8):700–6. [PubMed: 1883252]
4.
Simon GE, VonKorff M. Recognition, management, and outcomes of depression in primary care. Archives of Family Medicine. 1995;4(2):99–105. [PubMed: 7842160]
5.
Gilbody S, et al. Collaborative cares for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006;166(21):2314–21. [PubMed: 17130383]
6.
Gilbody S, Bower P, Whitty P. Costs and consequences of enhanced primary care for depression: systematic review of randomized economic evaluations. Br J Psychiatry. 2006;189:297–308. [PubMed: 17012652]
7.
Williams JW Jr, et al. Systematic review of multifaceted interventions to improve depression care. Gen Hosp Psychiatry. 2007;29(2):91–116. [PubMed: 17336659]
8.
Rubenstein LV, et al. Determining key features of effective depression interventions. V.A.H.S.R.D.S.E.-B.S. Program, Editor; Washington, DC: 2009. [PubMed: 21155205]
9.
Anonymous. Depression: Management in Primary and Secondary Care. National Institute for Health and Clinical Excellence; London: 2007. Clinical Guideline 23.
10.
Anonymous. Health Care Guideline: Major Depression in Adults in Primary Care. 11th edition. Institute for Clinical Systems Improvement; 2008. Available at: www​.icsi.org.
11.
Dalton SO, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163(1):59–64. [PubMed: 12523917]
12.
Richards JB, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188–94. [PubMed: 17242321]
13.
Diem SJ, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(12):1240–5. [PubMed: 17592096]
14.
Williams JW Jr, et al. Is this patient clinically depressed? JAMA. 2002;287(9):1160–70. [PubMed: 11879114]
15.
Williams JW Jr. Is this patient clinically depressed? In: Rennie SDLa., editor. The Rational Clinical Examination: Evidence-Based Clinical Diagnosis. McGraw Hill; 2009. pp. 247–264.
16.
Gilbody S, et al. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med. 2007;22(11):1596–602. [PMC free article: PMC2219806] [PubMed: 17874169]
17.
Faries D, et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000;34(1):3–10. [PubMed: 10696827]
18.
Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. Med Care. 1990;28(7):632–42. [PubMed: 2366602]
19.
Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials. 1991;12(4 Suppl):142S–158S. [PubMed: 1663851]
20.
Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis. 1987;40(2):171–8. [PubMed: 3818871]
21.
Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis. 1986;39(11):897–906. [PubMed: 2947907]
22.
Frank E, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851–5. [PubMed: 1929776]
23.
Panel DG. Depression in Primary Care: Volume 2. Treatment of Major Depression. U.S. Department of Health and Human Services, Agency for Health Care Policy and Research; Rockville, MD: Apr, 1993. Clinical Practice Guideline, Number 5., P.H.S.
24.
Beck A, Steer R, Brown G. BDI-II fast screen for medical patients manual. London: The Psychological Corporation; 2000.
25.
Andresen EM, et al. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale) Am J Prev Med. 1994;10(2):77–84. [PubMed: 8037935]
26.
Salokangas RK, Poutanen O, Stengard E. Screening for depression in primary care. Development and validation of the Depression Scale, a screening instrument for depression. Acta Psychiatr Scand. 1995;92(1):10–6. [PubMed: 7572242]
27.
D’Ath P, et al. Screening, detection and management of depression in elderly primary care attenders. I: The acceptability and performance of the 15 item Geriatric Depression Scale (GDS15) and the development of short versions. Fam Pract. 1994;11(3):260–6. [PubMed: 7843514]
28.
Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737–44. [PubMed: 10568646]
29.
Broadhead WE, et al. Development and validation of the SDDS-PC screen for multiple mental disorders in primary care. Arch Fam Med. 1995;4(3):211–9. [PubMed: 7881602]
30.
Atkins D, et al. Grading quality of evidence and strength of recommendations. Bmj. 2004;328(7454):1490. [PMC free article: PMC428525] [PubMed: 15205295]
31.
Lowe B, Kroenke K, Grafe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2) Journal of Psychosomatic Research. 2005;58(2):163–71. [PubMed: 15820844]
32.
Lowe B, et al. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9) Journal of Affective Disorders. 2004;81(1):61–6. [PubMed: 15183601]
33.
Löwe B, et al. Responsiveness of the PHQ-9 to psychopharmacological depression treatment. Psychosomatics. 2006;47(1):62–67. [PubMed: 16384809]
34.
Lowe B, et al. Monitoring depression treatment outcomes with the patient health questionnaire-9. Medical Care. 2004;42(12):1194–201. [PubMed: 15550799]
35.
Hansen R, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatric Services. 2008;59(10):1121–30. [PMC free article: PMC2840386] [PubMed: 18832497]
36.
Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. Journal of Consulting and Clinical Psychology. 2008;76(3):468–77. [PMC free article: PMC2648513] [PubMed: 18540740]
37.
Kocsis JH, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. Journal of Clinical Psychiatry. 2007;68(7):1014–23. [PubMed: 17685736]
38.
Gorwood P, et al. Escitalopram prevents relapse in older patients with major depressive disorder. American Journal of Geriatric Psychiatry. 2007;15(7):581–93. [PubMed: 17586783]
39.
Kornstein SG, et al. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75–225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study. International Clinical Psychopharmacology. 2008;23(6):357–63. [PMC free article: PMC3671869] [PubMed: 18854724]
40.
Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27(3 Suppl):S178–89. [PubMed: 2646488]
41.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16(9):606–13. [PMC free article: PMC1495268] [PubMed: 11556941]
42.
Kornstein SG, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67(11):1767–75. [PubMed: 17196058]
43.
Lepine JP, et al. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry. 2004;161(5):836–42. [PubMed: 15121648]
44.
Reimherr FW, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998;155(9):1247–53. [PubMed: 9734550]
45.
Oslin DW, et al. Screening, assessment, and management of depression in VA primary care clinics. The Behavioral Health Laboratory. J Gen Intern Med. 2006;21(1):46–50. [PMC free article: PMC1484620] [PubMed: 16423122]
46.
Dowrick C, et al. Patients’ and doctors’ views on depression severity questionnaires incentivized in UK quality and outcomes framework: qualitative study. BMJ. 2009;338:b663. [PubMed: 19299474]
47.
Nease DE Jr, et al. Inducing sustainable improvement in depression care in primary care practices. Jt Comm J Qual Patient Saf. 2008;34(5):247–55. [PubMed: 18491688]
48.
Duffy FF, et al. Systematic use of patient-rated depression severity monitoring: is it helpful and feasible in clinical psychiatry? Psychiatr Serv. 2008;59(10):1148–54. [PubMed: 18832500]
49.
Dietrich AJ, et al. Re-engineering systems for the treatment of depression in primary care: cluster randomized controlled trial. Bmj. 2004;329(7466):602. [PMC free article: PMC516659] [PubMed: 15345600]
50.
Unutzer J, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288(22):2836–45. [PubMed: 12472325]
51.
Ahava GW, et al. Is the Beck Depression Inventory reliable over time? An evaluation of multiple test-retest reliability in a nonclinical college student sample. Journal of Personality Assessment. 1998;70(2):222–31. [PubMed: 9697329]
52.
Adler DA, et al. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. General Hospital Psychiatry. 2004;26(3):199–209. [PubMed: 15121348]
53.
Allard P, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blindrandomized 6-month comparative trial with citalopram International Journal of Geriatric Psychiatry 200419(12):1123–30. [PubMed: 15526307]
54.
Altamura AC, et al. Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clinical Neuropharmacology. 1989;12(Suppl 1):S25–33. S34–7. [PubMed: 2663151]
55.
Amsterdam JD, Shults J, Rutherford N. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008;32(1):100–6. [PubMed: 17804135]
56.
Babyak M, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosomatic Medicine. 2000;62(5):633–8. [PubMed: 11020092]
57.
Baldwin D, Moreno RA, Briley M. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum Psychopharmacol. 2008;23(6):527–32. [PubMed: 18536065]
58.
Barbosa L, Berk M, Vorster M. A double-blind randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry. 2003;64(4):403–7. [PubMed: 12716240]
59.
Berkman LF, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289(23):3106–16. [PubMed: 12813116]
60.
Berlim MT, et al. Reliability and validity of the WHOQOL BREF in a sample of Brazilian outpatients with major depression. Quality of Life Research. 2005;14(2):561–4. [PubMed: 15892446]
61.
Berlim MT, et al. Significant-patients 12 weeks following the start of antidepressants. Psychiatry Research. 2007;153(3):253–9. [PubMed: 17675247]
62.
Boyer P, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics. 1998;13(1 Pt 2):157–69. [PubMed: 10184835]
63.
Brody BL, et al. Age-related macular degeneration: self-management and reduction of depressive symptoms in a randomized, controlled study. Journal of the American Geriatrics Society. 2006;54(10):1557–62. [PubMed: 17038074]
64.
Brown C, Schulberg HC, Prigerson HG. Factors associated with symptomatic improvement and recovery from major depression in primary care patients. General Hospital Psychiatry. 2000;22(4):242–50. [PubMed: 10936631]
65.
Brown ES, et al. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study. Biological Psychiatry. 2005;58(11):865–70. [PubMed: 15993860]
66.
Cassidy EL, Lauderdale S, Sheikh JI. Mixed anxiety and depression in older adults: clinical characteristics and management. Journal of Geriatric Psychiatry and Neurology. 2005;18(2):83–8. [PubMed: 15911936]
67.
Casten RJ, et al. A comparison of self-reported function assessed before and after depression treatment among depressed geriatric patients. International Journal of Geriatric Psychiatry. 2000;15(9):813–818. [PubMed: 10984727]
68.
Chen TM, et al. Using the PHQ-9 for depression screening and treatment monitoring for Chinese Americans in primary care. Psychiatric Services. 2006;57(7):976–81. [PubMed: 16816282]
69.
Conradi HJ, et al. Enhanced treatment for depression in primary care: long-term outcomes of a psycho-educational prevention program alone and enriched with psychiatric consultation or cognitive behavioral therapy. Psychological Medicine. 2007;37(6):849–62. [PubMed: 17376257]
70.
Cook IA, et al. Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Research. 1999;85(3):263–73. [PubMed: 10333379]
71.
Corney R, Simpson S. Thirty-six month outcome data from a trial of counseling with chronically depressed patients in a general practice setting. Psychology and Psychotherapy: Theory, Research and Practice. 2005;78(1):127–138. [PubMed: 15826410]
72.
Coulehan JL, et al. Treating depressed primary care patients improves their physical, mental, and social functioning. Archives of Internal Medicine. 1997;157(10):1113–20. [PubMed: 9164377]
73.
Dalton EJ, et al. Use of slow-release melatonin in treatment-resistant depression. Journal of Psychiatry and Neuroscience. 2000;25(1):48–52. [PMC free article: PMC1407707] [PubMed: 10721684]
74.
Davies J, et al. Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression. American Journal of Psychiatry. 2003;160(2):374–6. [PubMed: 12562589]
75.
DeBattista C, et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. Journal of Clinical Psychopharmacology. 2003;23(1):27–30. [PubMed: 12544372]
76.
Dori GA, Overholser JC. Evaluating depression severity and remission with a modified Beck Depression Inventory. Personality and Individual Differences. 2000;28(6):1045–1061.
77.
Dubovsky SL, et al. Nicardipine improves the antidepressant action of ECT but does not improve cognition. Journal of ECT. 2001;17(1):3–10. [PubMed: 11281512]
78.
Dunner D, et al. Adinazolam--a new antidepressant: findings of a placebo-controlled, double-blind study in outpatients with major depression. Journal of Clinical Psychopharmacology. 1987;7(3):170–2. [PubMed: 3298327]
79.
Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. International Clinical Psychopharmacology. 2004;19(5):305–10. [PubMed: 15289704]
80.
Fava M, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. Journal of Clinical Psychopharmacology. 1999;19(4):329–35. [PubMed: 10440460]
81.
Fawcett J, et al. Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients. Journal of Clinical Psychopharmacology. 1987;7(5):295–310. [PubMed: 3316312]
82.
George T, et al. An open study of sertraline in patients with major depression who failed to respond to moclobemide. Australian and New Zealand Journal of Psychiatry. 1999;33(6):889–95. [PubMed: 10619217]
83.
George TP, et al. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. Journal of Clinical Psychopharmacology. 2008;28(3):340–4. [PubMed: 18480694]
84.
Goodnick PJ, et al. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacology Bulletin. 1997;33(2):261–4. [PubMed: 9230640]
85.
Goodnick PJ, et al. Bupropion slow-release response in depression: diagnosis and biochemistry. Biological Psychiatry. 1998;44(7):629–32. [PubMed: 9787888]
86.
Judd LL, et al. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. American Journal of Psychiatry. 2004;161(10):1864–71. [PubMed: 15465984]
87.
Kates N, et al. Counselors in primary care: benefits and lessons learned. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie. 2002;47(9):857–62. [PubMed: 12500756]
88.
Koivumaa-Honkanen H, et al. Mental health and well-being in a 6-year follow-up of patients with depression: assessments of patients and clinicians. Social Psychiatry and Psychiatric Epidemiology. 2008;43(9):688–96. [PubMed: 18438597]
89.
Koran LM, et al. Predicting response to fluoxetine in geriatric patients with major depression. Journal of Clinical Psychopharmacology. 1995;15(6):421–7. [PubMed: 8748431]
90.
Kroenke K, et al. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. Journal of Clinical Psychiatry. 2006;67(1):72–80. [PubMed: 16426091]
91.
Lesperance F, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297(4):367–79. [PubMed: 17244833]
92.
Lett HS, et al. Social support and prognosis in patients at increased psychosocial risk recovering from myocardial infarction. Health Psychology. 2007;26(4):418–427. [PubMed: 17605561]
93.
Levitt AJ, et al. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? Journal of Clinical Psychiatry. 1999;60(9):613–6. [PubMed: 10520980]
94.
Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. Journal of Clinical Psychiatry. 2007;68(11):1663–72. [PubMed: 18052559]
95.
Lustman PJ, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Annals of Internal Medicine. 1998;129(8):613–21. [PubMed: 9786808]
96.
Lustman PJ, et al. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000;23(5):618–23. [PubMed: 10834419]
97.
Lydiard RB, et al. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. Journal of Clinical Psychiatry. 1997;58(11):484–91. [PubMed: 9413414]
98.
Mazeh D, et al. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. International Clinical Psychopharmacology. 2007;22(6):371–5. [PubMed: 17917556]
99.
McIntyre RS, et al. Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ. 2005;173(11):1327–34. [PMC free article: PMC1283499] [PubMed: 16301700]
100.
Mohamed S, et al. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial. Am J Geriatr Pharmacother. 2006;4(3):201–9. [PubMed: 17062320]
101.
Mulrow CD, et al. Treatment of depression--newer pharmacotherapies. Psychopharmacology Bulletin. 1998;34(4):409–795. [PubMed: 10513454]
102.
Mynors-Wallis LM, et al. Randomized controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ. 2000;320(7226):26–30. [PMC free article: PMC27250] [PubMed: 10617523]
103.
Patkar AA, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. Journal of Clinical Psychopharmacology. 2006;26(6):653–6. [PubMed: 17110825]
104.
Perez V, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Archives of General Psychiatry. 1999;56(4):375–9. [PubMed: 10197835]
105.
Picardi A, et al. Screening for depressive disorders in patients with skin diseases: a comparison of three screeners. Acta Dermato-Venereologica. 2005;85(5):414–9. [PubMed: 16159733]
106.
Pollock BG, et al. Acute antidepressant effect following pulse loading with intravenous and oral clomipramine. Archives of General Psychiatry. 1989;46(1):29–35. [PubMed: 2642691]
107.
Posternak MA, Miller I. Untreated short-term course of major depression: a meta-analysis of outcomes from studies using wait-list control groups. Journal of Affective Disorders. 2001;66(2–3):139–46. [PubMed: 11578666]
108.
Proudfoot J, et al. Computerized, interactive, multimedia cognitive-behavioral program for anxiety and depression in general practice. Psychological Medicine. 2003;33(2):217–27. [PubMed: 12622301]
109.
Pyne JM, et al. Use of the quality of well-being self-administered version (QWB-SA) in assessing health-related quality of life in depressed patients. Journal of Affective Disorders. 2003;76(1–3):237–47. [PubMed: 12943954]
110.
Quilty LC, Meusel LA, Bagby RM. Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. Journal of Affective Disorders. 2008;111(1):67–73. [PubMed: 18384882]
111.
Raskin J, et al. Duloxetine in the long-term treatment of major depressive disorder. Journal of Clinical Psychiatry. 2003;64(10):1237–44. [PubMed: 14658974]
112.
Raskin J, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. American Journal of Psychiatry. 2007;164(6):900–9. [PubMed: 17541049]
113.
Rollman BL, et al. A randomized trial using computerized decision support to improve treatment of major depression in primary care. Journal of General Internal Medicine. 2002;17(7):493–503. [PMC free article: PMC1495078] [PubMed: 12133139]
114.
Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depression and Anxiety. 2005;21(1):26–32. [PubMed: 15786487]
115.
Rutherford B, et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. International Journal of Geriatric Psychiatry. 2007;22(10):986–91. [PubMed: 17340654]
116.
Salkovskis P, et al. A randomized controlled trial of the use of self-help materials in addition to standard general practice treatment of depression compared to standard treatment alone. Psychological Medicine. 2006;36(3):325–33. [PubMed: 16332282]
117.
Shelton RC, et al. Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978–86. [PubMed: 11308434]
118.
Singh NA, Clements KM, Singh MA. The efficacy of exercise as a long-term antidepressant in elderly subjects: a randomized, controlled trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2001;56(8):M497–504. [PubMed: 11487602]
119.
Skevington SM, Wright A. Changes in the quality of life of patients receiving antidepressant medication in primary care: Validation of the WHOQOL-100. British Journal of Psychiatry. 2001;178:261–267. [PubMed: 11230038]
120.
Spalletta G, Pasini A, Caltagirone C. Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial. Journal of Clinical Psychopharmacology. 2002;22(3):263–6. [PubMed: 12006896]
121.
Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. Journal of Clinical Psychiatry. 1985;46(3 Pt 2):53–8. [PubMed: 3882682]
122.
Szegedi A, et al. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John’s wort): randomized controlled double blind non-inferiority trial versus paroxetine. BMJ. 2005;330(7490):503. [PMC free article: PMC552808] [PubMed: 15708844]
123.
Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. Journal of Clinical Psychiatry. 1997;58(9):393–8. [PubMed: 9378690]
124.
Trivedi MH, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Archives of General Psychiatry. 2004;61(7):669–80. [PubMed: 15237079]
125.
Tutty S, Simon G, Ludman E. Telephone counseling as an adjunct to antidepressant treatment in the primary care system. A pilot study. Effective Clinical Practice. 2000;3(4):170–8. [PubMed: 11183432]
126.
van Gurp G, et al. St John’s wort or sertraline? Randomized controlled trial in primary care. Canadian Family Physician. 2002;48:905–12. [PMC free article: PMC2214056] [PubMed: 12053635]
127.
van Marwijk HW, et al. Primary care management of major depression in patients aged > or =55 years: outcome of a randomized clinical trial. British Journal of General Practice. 2008;58(555):680–6. I–II. discussion 687. [PMC free article: PMC2553526] [PubMed: 18826778]
128.
Vinkers DJ, et al. The 15-item Geriatric Depression Scale (GDS-15) detects changes in depressive symptoms after a major negative life event. The Leiden 85-plus Study. International Journal of Geriatric Psychiatry. 2004;19(1):80–4. [PubMed: 14716703]
129.
Wade AG, et al. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Pharmacoeconomics. 2008;26(11):969–81. [PubMed: 18850765]
130.
Wise TN, et al. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. International Journal of Clinical Practice. 2007;61(8):1283–93. [PMC free article: PMC2408656] [PubMed: 17590215]
131.
Bauer M, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. European Archives of Psychiatry and Clinical Neuroscience. 2009 [PubMed: 19165525]
132.
Gartlehner G, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Annals of Internal Medicine. 2008;149(10):734–50. [PubMed: 19017592]
133.
Qaseem A, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine. 2008;149(10):725–33. [PubMed: 19017591]
134.
Anderson IM, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343–96. [PubMed: 18413657]
135.
Papakostas GI, et al. Antidepressant dose reduction and the risk of relapse in major depressive disorder. Psychotherapy and Psychosomatics. 2007;76(5):266–70. [PubMed: 17700046]
136.
Furukawa TA, et al. Long-term treatment of depression with antidepressants: a systematic narrative review. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie. 2007;52(9):545–52. [PubMed: 17953158]
137.
Zimmerman M, Posternak MA, Ruggero CJ. Impact of study design on the results of continuation studies of antidepressants. Journal of Clinical Psychopharmacology. 2007;27(2):177–81. [PubMed: 17414242]
138.
Lam RW, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie. 2004;49(3 Suppl 1):17S–26S. [PubMed: 15147033]
139.
Dombrovski AY, et al. Maintenance treatment for old-age depression preserves health-related quality of life: a randomized. controlled trial of paroxetine and interpersonal psychotherapy. Journal of the American Geriatrics Society. 2007;55(9):1325–32. [PubMed: 17767673]
140.
Keller MB, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. Journal of Clinical Psychiatry. 2007;68(8):1246–56. [PubMed: 17854250]
141.
Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry. 1992;160:217–22. [PubMed: 1540762]
142.
Feiger AD, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol. 1999;14(1):19–28. [PubMed: 10221638]
143.
Gelenberg AJ, et al. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry. 2003;54(8):806–17. [PubMed: 14550680]
144.
Gilaberte I, et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol. 2001;21(4):417–24. [PubMed: 11476126]
145.
Hochstrasser B, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry. 2001;178:304–10. [PubMed: 11282808]
146.
Keller MB, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA. 1998;280(19):1665–72. [PubMed: 9831997]
147.
Klysner R, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry. 2002;181:29–35. [PubMed: 12091260]
148.
Lustman PJ, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(5):521–9. [PubMed: 16651509]
149.
Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol. 1993;8(3):181–8. [PubMed: 8263316]
150.
Montgomery SA, et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry. 2004;65(3):328–36. [PubMed: 15096071]
151.
Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 1993;8(3):189–95. [PubMed: 8263317]
152.
Reynolds CF 3rd, et al. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354(11):1130–8. [PubMed: 16540613]
153.
Robert P, Montgomery SA. Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol. 1995;10(Suppl 1):29–35. [PubMed: 7622809]
154.
Schmidt ME, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry. 2000;61(11):851–7. [PubMed: 11105738]
155.
Simon JS, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res. 2004;38(3):249–57. [PubMed: 15003430]
156.
Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1998;13(2):55–62. [PubMed: 9669185]
157.
Thase ME, et al. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry. 2001;62(10):782–8. [PubMed: 11816867]
158.
Weihs KL, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry. 2002;51(9):753–61. [PubMed: 11983189]
159.
Wilson KC, et al. Older community residents with depression: long-term treatment with sertraline. Randomized, double-blind, placebo-controlled study. Br J Psychiatry. 2003;182:492–7. [PubMed: 12777339]
Bookshelf ID: NBK49039

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.2M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...